



Correction to ASX announcement

Brisbane, Australia, 3 August 2022 – ResApp Health Limited (ASX:RAP) (**ResApp**) refers to the ASX announcement released earlier today regarding ResApp's entry into a further amended and restated scheme implementation deed. ResApp wishes to clarify that it has not yet submitted a draft supplementary explanatory statement to the Supreme Court of New South Wales. ResApp intends to file the draft supplementary explanatory statement with the Supreme Court of New South Wales as soon as possible and will update shareholders on the outcome of the court process once it has concluded.

###

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test; SleepCheckRx, a prescription-only smartphone application that screens adults for moderate to severe sleep apnoea; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. For more information, please visit www.resapphealth.com.au.

Contacts

Dr Tony Keating
CEO and Managing Director
+61 430 180 659
tony@resapphealth.com.au

Mr Brian Leedman
Executive Director, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au

This ASX announcement was approved and authorised for release by the Managing Director of ResApp Health.